*: ITT population. †: One patient assigned to the placebo group received one dose of pertuzumab in error and was included in the safety population for the pertuzumab group; Final safety population: pertuzumab (n=385), placebo (n=388). ‡: These patients were enrolled in the study but ...
Purpose: This study aims to evaluate the efficacy and safety of trastuzumab biosimilar (HLX02) in combination with pertuzumab and chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) after progression of trastuzumab. Mate...
除最初的Tz-PHF-vinca,XMT-1522也是利用该技术平台构建,平均DAR值为12,抗体与HER2的结合表位不同于Trastuzumab/Pertuzumab;在小鼠异种移植模型中具有较高的抗肿瘤作用(单剂量0.67 mg/kg),并且在对Tz-DM1不敏感的HER2+表达模型中可延长无瘤生存期(单剂量2 mg/kg),其治疗指数(TI) >40,这与其内化释放的AF-HPA...
Anne Laure Martin; Christiane Ölschlegel; Marie- Aline Gérard; Michael Gnant; Sybille Loibl; Carlo Tondini JAMA Oncology Comment & Response Pertuzumab Plus Trastuzumab Without Chemotherapy for ERBB2-Positive Metastatic Breast Cancer—Reply Jens Huober, MD; Beat Thürlimann, MD; Daniel Dietrich, Ph...
for patients who are presenting with stage two or three HER2-positive breast cancer. It's given preoperatively along with chemotherapy then the patients go to surgery. If they're a pathologic complete response, then they can continue the trastuzumab and pertuzumab subcutaneously to finish up th...
Trastuzumab and pertuzumab in hemodialysis: A case report. PMID: 33779370Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer. PMID: 36259134Trastuzumab emtansine and cost-based decision making. PMID: 28091366Is weight-based IV dosing of trastuzumab preferable to SC ...
Huober J, Barrios CH, Niikura N, et al. Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): final results of the phase III IMpassion050 trial. Ann Oncol. 2024;9(suppl 4):1-25. doi:10.1016/esmoop/esmoop103096 ...
Pertuzumab (a type of monoclonal antibody) Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate) Tucatinib (Tyrosine Kinase HER2 Inhibitor) Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate) ...
Advanced gastric cancer(AGC) is associated with a high mortality rate and, despite multiple new chemotherapy options, the survival rates of patients with A... O Yazici,MAN Sendur,N Ozdemir,... - 《World Journal of Gastroenterology》 被引量: 26发表: 2016年 食管癌靶向治疗的研究进展 近年来手...
Pertuzumab联合trastuzumab和化疗一线治疗转移性HER2胃或胃食管交界癌(JACOB)研究解读 本期分享的是2018年9月11日发表在Lancet Oncol上的JACOB研究的最终分析。JACOB研究旨在比较帕妥珠单抗(pertuzumab)联合曲妥珠单抗(tratuzumab)和化疗对比tratuzumab和化疗一线治疗转移性HER2阳性的胃或胃食管交界癌患者,以探讨在目前trat...